Midomafetamine HCl: Clinical Trials

20 trials of Midomafetamine HCl, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 3 withdrawn, 2 terminated, 1 active not recruiting. 11 Phase 2, 6 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 7, Terminated 2, Withdrawn 2
Phase 16Completed 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 32Completed 2

Follow Midomafetamine HCl: new trials by email Literature Review of Midomafetamine HCl trials Research Report on Midomafetamine HCl

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Midomafetamine in Healthy Adults
Midomafetamine HCl - Healthy Volunteers
Phase 1Active not recruitingResilient Pharmaceuticals322026-04-232026-06-29
MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
Midomafetamine HCl - Pharmacokinetics, Hepatic Impairment
Phase 1Not yet recruitingResilient Pharmaceuticals162026-03-292024-10-30
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders
Midomafetamine, Non-directive therapy, Therapy - Anorexia Nervosa Restricting Type, Binge-Eating Disorder
Phase 2WithdrawnResilient Pharmaceuticals2026-02-012024-10-31
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)
Midomafetamine HCl, Therapy - Psychological Effects of Study Drug
Phase 1WithdrawnResilient Pharmaceuticals2024-12-012024-10-31
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
midomafetamine, Therapy - Posttraumatic Stress Disorder
Phase 2WithdrawnResilient Pharmaceuticals2022-08-012024-11-01
Food Effects on Bioavailability of MDMA in Healthy Volunteers
midomafetamine - Pharmacokinetics
Phase 1CompletedResilient Pharmaceuticals142022-07-282024-10-30
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
Midomafetamine, Psychotherapy - PTSD
Phase 2TerminatedResilient Pharmaceuticals262021-11-082025-07-15
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
Midomafetamine HCl - PTSD
Phase 3CompletedResilient Pharmaceuticals872021-03-082025-06-06
Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study
Midomafetamine HCl - PTSD
Phase 2CompletedMAPS Europe B.V.212020-06-242025-01-28
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
Therapy, midomafetamine HCl, Placebo - Posttraumatic Stress Disorder
Phase 3CompletedResilient Pharmaceuticals1002018-11-212025-06-06
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)
Midomafetamine HCl, Manualized therapy - Posttraumatic Stress Disorder
Phase 2CompletedResilient Pharmaceuticals42018-03-132025-06-10
Evaluation of MDMA on Startle Response
Placebo, Midomafetamine, Acoustic startle - Startle Response
Phase 1CompletedResilient Pharmaceuticals342017-03-142025-03-04
MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness
Midomafetamine HCl, Placebo, Therapy - Anxiety
Phase 2CompletedResilient Pharmaceuticals182015-05-142025-06-05
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
Placebo, Midomafetamine HCl, Psychotherapy - Posttraumatic Stress Disorder
Phase 2TerminatedResilient Pharmaceuticals62014-10-142025-06-05
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
Placebo, Midomafetamine HCl, Therapy - Social Anxiety in Autistic Adults
Phase 2CompletedResilient Pharmaceuticals122014-04-112025-06-05
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl - Posttraumatic Stress Disorder
Phase 2CompletedResilient Pharmaceuticals292013-05-132025-06-05
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
Active Placebo Dose MDMA-assisted therapy (25 mg), Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg) - Posttraumatic Stress Disorder (PTSD)
Phase 2CompletedResilient Pharmaceuticals102013-01-172025-06-06
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers
Lactose (inactive placebo), midomafetamine HCl - Psychological Effects of Study Drug
Phase 1CompletedResilient Pharmaceuticals1072011-04-092024-10-31
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
Midomafetamine HCl, Lactose placebo pill, Therapy - Posttraumatic Stress Disorder
Phase 2CompletedResilient Pharmaceuticals232004-03-122025-06-06
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD
Midomafetamine, Psychotherapy - Post Traumatic Stress Disorder
No longer availableResilient Pharmaceuticals2024-11-05

Conditions studied

Stress Disorders, Post-Traumatic (11)  ·  Anxiety Disorders (1)  ·  Autistic Disorder (1)  ·  Binge-Eating Disorder (1)  ·  Depression (1)

Sponsors

Resilient Pharmaceuticals (19)  ·  MAPS Europe B.V. (1)

Countries

United States (13)  ·  Canada (4)  ·  Israel (3)  ·  Czechia (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Norway (1)  ·  United Kingdom (1)

Top investigators

Adele Lafrance, PhD (1)  ·  Barbara Rothbaum (1)  ·  Bessel van der Kolk, MD (1)  ·  Caroline Lewis, MD (1)  ·  Casey Paleos, MD (1)  ·  Charles S. Grob, MD (1)  ·  Cole Marta, MD (1)  ·  Devon Christie, MD (1)  ·  Emma Hapke, MD (1)  ·  Ingrid Pacey, MBBS FRCP[C] (1)  ·  Janel Long-Boyle, PharmD, PhD (1)  ·  Josh Woolley, MD, PhD (1)  ·  Manish Agrawal, MD (1)  ·  Marcela Ot'alora (1)

Results publications

PMID 31065731, PMID 31572236, PMID 32500209, PMID 20643699, PMID 23172889, PMID 25818246, PMID 30196397, PMID 33235285, PMID 33972795, PMID 35166140, PMID 38174611, PMID 38198456